ccx559
chemocentryx
['$ccxi', 'chemocentryx']
$ccxi chemocentryx reports safety results available from ongoing phase i trial of orally administered pd-l1 inhibitor, ccx559, at the 2022 american society of clinical oncology (asco) annual meeting 45 seconds delayed.
Democratizing insights.

Not investment advice.